Grifols successfully completes refinancing of 2027 maturities, further strengthening balance sheet and extending debt profile

Barcelona, Spain, April 14, 2026 –  Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B (TLB), alongside a revolving credit facility. The transaction enhances the company’s financial flexibility, extends its debt maturity profile, and reinforces its liquidity position.

The new financing package totals over $5.3 billion equivalent and is structured across three tranches, including a U.S. dollar-denominated term loan of $2.00 billion, a euro-denominated tranche of €1.25 billion, and a revolving credit facility with total commitments of approximately $2.06 billion. The term loans have a maturity of seven years, while the revolving credit facility has a maturity of six and a half years.

The transaction was met with strong demand from a broad base of global institutional investors, with particularly robust participation from U.S. accounts. This allowed for a significant upsizing of the transaction and improved economic terms across both tranches, reflecting increasing confidence in Grifols’ financial trajectory and execution.

The U.S. dollar tranche was priced at SOFR + 250 basis points with an original issue discount (OID) of 99.25, while the euro tranche was priced at Euribor + 300 basis points with an OID of 99.75. Both facilities include leverage-based margin step-down mechanisms.

Proceeds from the transaction have been used to fully refinance the company’s existing 2027 debt maturities, including the repayment of the 2019 Term Loan B and the redemption of the remaining outstanding 2019 Notes, while also providing additional liquidity to support the Group’s development.

Combined with the previously announced €500 million partial redemption of its 7.5% Senior Secured Notes due 2030, the transaction further strengthens Grifols’ balance sheet, reducing funded gross debt, lowering cash interest expense and extending its debt maturity profile.

As a result, Grifols has no significant debt maturities until October 2028 and maintains a strong liquidity position.